Masahiro Nakano1, Mamiko Fujisue2, Rumiko Tashima3, Yasuhiro Okumura2, Yasuyuki Nishiyama2, Tomofumi Ohsako2, Yasuo Toyozumi4, Nobuyuki Arima4, Reiki Nishimura2. 1. Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60, Kotoh, Higashi-ku, Kumamoto 860-8505, Japan. Electronic address: mnakano1020@gmail.com. 2. Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60, Kotoh, Higashi-ku, Kumamoto 860-8505, Japan. 3. Department of Surgery, Kumamoto City Hospital, 1-1-60, Kotoh, Higashi-ku, Kumamoto 860-8505, Japan. 4. Department of Pathology, Kumamoto City Hospital, 1-1-60, Kotoh, Higashi-ku, Kumamoto 860-8505, Japan.
Abstract
BACKGROUND: Survival for patients with recurrent breast cancer has improved over time due to the introduction of modern systemic therapy. The aim of this study was to determine the impact of subtype and the year of recurrence on the survival times of recurrent breast cancer. METHODS: Between 1979 and 2013, 813 patients who underwent initial treatment for primary breast cancer experienced recurrence. They were divided into two groups based on the year of recurrence; before 2000 and after 2001. Survival after recurrence was compared between these groups based on following criteria; subtypes, disease free interval (DFI), and dominant recurrent site. The median follow-up period after recurrence was 4.3 years. RESULTS: Survival improved significantly in the after 2001 group, and a significant improvement in survival was only seen in the HER2-enriched subtype. Multivariate analysis revealed that DFI, ER, HER2 status, dominant recurrent site and the Ki-67 index value were significant prognostic factors. In the HER2-enriched subtype, the year of recurrence, DFI and dominant recurrent site were significant independent factors. In the other subtypes, these factors were not correlated with survival. CONCLUSION: Our study revealed that the survival rate of patients with only the HER2-enriched subtype significantly improved after recurrence. To prolong the survival time after recurrence of both luminal and triple negative subtypes, the development of novel targeting therapies to overcome refractory recurrent breast cancer is extremely important.
BACKGROUND: Survival for patients with recurrent breast cancer has improved over time due to the introduction of modern systemic therapy. The aim of this study was to determine the impact of subtype and the year of recurrence on the survival times of recurrent breast cancer. METHODS: Between 1979 and 2013, 813 patients who underwent initial treatment for primary breast cancer experienced recurrence. They were divided into two groups based on the year of recurrence; before 2000 and after 2001. Survival after recurrence was compared between these groups based on following criteria; subtypes, disease free interval (DFI), and dominant recurrent site. The median follow-up period after recurrence was 4.3 years. RESULTS: Survival improved significantly in the after 2001 group, and a significant improvement in survival was only seen in the HER2-enriched subtype. Multivariate analysis revealed that DFI, ER, HER2 status, dominant recurrent site and the Ki-67 index value were significant prognostic factors. In the HER2-enriched subtype, the year of recurrence, DFI and dominant recurrent site were significant independent factors. In the other subtypes, these factors were not correlated with survival. CONCLUSION: Our study revealed that the survival rate of patients with only the HER2-enriched subtype significantly improved after recurrence. To prolong the survival time after recurrence of both luminal and triple negative subtypes, the development of novel targeting therapies to overcome refractory recurrent breast cancer is extremely important.
Authors: Molly Scannell Bryan; Maria Argos; Irene L Andrulis; John L Hopper; Jenny Chang-Claude; Kathleen Malone; Esther M John; Marilie D Gammon; Mary Daly; Mary Beth Terry; Saundra S Buys; Dezheng Huo; Olofunmilayo Olopade; Jeanine M Genkinger; Farzana Jasmine; Muhammad G Kibriya; Lin Chen; Habibul Ahsan Journal: Breast Cancer Res Treat Date: 2017-05-13 Impact factor: 4.872
Authors: Samuel Rosas; Karim Sabeh; Jennifer Kurowicki; Leonard Buller; Tsun Yee Law; Martin Roche; Sheila Conway; Victor H Hernandez Journal: Ann Transl Med Date: 2017-12
Authors: S A M Gernaat; P J Ho; N Rijnberg; M J Emaus; L M Baak; M Hartman; D E Grobbee; H M Verkooijen Journal: Breast Cancer Res Treat Date: 2017-05-13 Impact factor: 4.872
Authors: Jennifer L Caswell-Jin; Sylvia K Plevritis; Lu Tian; Christopher J Cadham; Cong Xu; Natasha K Stout; George W Sledge; Jeanne S Mandelblatt; Allison W Kurian Journal: JNCI Cancer Spectr Date: 2018-12-24